NCT06816992 - ORIC-114 in Combination with Subcutaneous Amivantamab in Patients with EGFR Exon20 Insertion Mutant NSCLC | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

February 27, 2025

Primary Completion Date

May 31, 2026

Study Completion Date

May 31, 2027

Conditions

Solid TumorsEGFR Exon 20 Insertion MutationsNSCLCEGFR-mutated NSCLC

Interventions

DRUG

ORIC-114 Dose 1 + amivantamab

ORIC-114 oral daily, amivantamab subcutaneous weekly for 4 weeks followed by every 4 week injection

DRUG

ORIC-114 Dose 2 + amivantamab

ORIC-114 oral daily, amivantamab subcutaneous weekly for 4 weeks followed by every 4 week injection

DRUG

ORIC-114 Dose 3 + amivantamab

ORIC-114 oral daily, amivantamab subcutaneous weekly for 4 weeks followed by every 4 week injection

Trial Locations (4)

RECRUITING

NYU Langone Health, New York

RECRUITING

Virginia Cancer Specialists, Fairfax

NOT_YET_RECRUITING

Peter MacCallum Cancer Centre, Melbourne

NOT_YET_RECRUITING

The Princess Margaret Hospital, Toronto